{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-035203","form_type":"8-K","ticker":"COGT","cik":"0001622229","company_name":"Cogent Biosciences, Inc.","filed_at":"2024-02-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.843523+00:00","generated_at":"2026-06-06T02:23:10.928600+00:00","sec_items":["1.01","5.03","3.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Cogent Biosciences raises $225M in oversubscribed PIPE at $7.50/share, 37% premium","bullets":["Gross proceeds of $225M from 17.7M common shares at $7.50 and Series B convertible preferred.","Pro-forma cash expected to fund into 2027 through SUMMIT, PEAK, and APEX registration trials.","Led by Commodore Capital; includes Fairmount, Redmile, Janus, TCGX, Adage, Venrock, Deerfield, Perceptive.","Investor webcast on Feb 23 to review SUMMIT Part 1b data at AAAAI annual meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-035203","json":"https://secwatch.observer/filing/0001193125-24-035203.json","markdown":"https://secwatch.observer/filing/0001193125-24-035203.md","text":"https://secwatch.observer/filing/0001193125-24-035203.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1622229/000119312524035203/0001193125-24-035203-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1622229/000119312524035203/d790187d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T02:23:10.928600+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"99dbcb92c845e7e711a89833da51f0e9d45b1b6b","claim":"Cogent Biosciences, Inc.: Filed Certificate of Designation for Series B Non-Voting Convertible Preferred Stock, establishing the powers, preferences, rights, and limitations of the new series (effective 2024-02-14).","evidence_excerpt":"On February 14, 2024, the Company filed a Certificate of Designations of Preferences, Rights and Limitations of the Series B Non-Voting Convertible Preferred Stock with the Secretary of State of the State of Delaware (the “ Certificate of Designation ”) in connection with the Private Placement.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1622229/000119312524035203/0001193125-24-035203-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2024-02-14"}],"fact_type":"governance_change"},{"claim_id":"923d6aa737e29a7ffa31cd6ef6910b35c0e0c018","claim":"Cogent Biosciences, Inc. entered into Securities Purchase Agreement with certain institutional and accredited investors valued at approximately $225 million (effective 2024-02-13).","evidence_excerpt":"On February 13, 2024, Cogent Biosciences, Inc., a Delaware corporation (the “ Company ”), entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) for a private placement (the “ Private Placement ”) with certain institutional and accredited investors (each, a “ Purchaser ” and collectively, the “ Purchasers ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1622229/000119312524035203/0001193125-24-035203-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain institutional and accredited investors"},{"label":"Value","value":"approximately $225 million"},{"label":"Effective","value":"2024-02-13"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}